Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now X
ETFs with INSM as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|1.9%||SPDR S&P Biotech ETF (XBI)||+43.37 (26.89%)|
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
Insmed is a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. Our lead product candidate, ARIKAYCE®, or liposomal amikacin for inhalation (LAI), is an inhaled antibiotic treatment that delivers a proven and potent anti-infective directly to the site of serious lung infections. We are currently conducting a phase 2 clinical trial in the United States (US) and Canada of ARIKAYCE in patients who have lung infections caused by non-tuberculous mycobacteria (NTM) and we expect to report top-line clinical results from the double-blind phase of this clinical trial in March 2014. In 2013, we concluded a phase 3 clinical trial in Europe and Canada of ARIKAYCE in cystic fibrosis (CF) patients who have lung infections caused by Pseudomonas aeruginosa (Pseudomonas). The CF and NTM target indications address orphan patient populations. ... More ...
Where does INSM fit in the risk graph?
|Annual EPS Est:||$-1.6|
|Quarterly EPS Est:||-0.56|